Acute Myeloid Leukemia Therapeutics Market by Product (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-Metabolites, Tyrosine Kinase Inhibitors, and Hormonal Therapy) - Global Opportunity Analysis and Industry Forecast, 2019-2026
|
LI_183721
|
Pages: NA
|
Jan 2020 |
1472 Views
|
|
|
|
Author(s) :
NA
|
Tables: NA
|
Charts: NA
|
Formats*:
|
|
Acute myeloid leukemia (AML), is a type of blood cancer which usually affects white blood cells (WBCs), however, it can also start in other types of blood-forming cells. In AML, there is a fast production of the abnormal WBCs that get accumulated in the bone marrow, and affect the production of normal blood cells.
The major factors that drive the market growth include advantages of biopharmaceuticals over conventional medicines, rise in geriatric population, unhealthy lifestyle, strong biopharmaceutical pipeline, and development of combination therapies that can treat diseases that were previously untreated. However, high cost of the therapeutic process, and its safety concerns, is expected to hinder the growth of the market. Moreover, ongoing researches have led to discovery of more efficient therapies for cancer treatment, which pose attractive opportunities for the key market players.
The global acute myeloid leukemia therapeutics market is segmented on the basis of treatment type and geography. According to treatment type, the market is divided into cytarabine, anthracycline drugs, alkylating agents, anti-metabolites, tyrosine kinase inhibitors, hormonal therapy, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key players profiled in the report include Eli Lilly and Company, Genzyme Corporation, Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Celegene Corporation, Cephalon, Inc., and Eisai Inc.
Key Benefits
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It presents a quantitative analysis from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market by type elucidates the regional trends.
- Key players and their strategies are analyzed to understand the competitive outlook of the market.
Acute Myeloid Leukemia Therapeutics Market Key Segments:
By Treatment Type
- Cytarabine
- Anthracycline Drugs
- Daunomycin
- Idarubicin
- Mitoxantrone
- Alkylating Agents
- Anti-Metabolites
- Tyrosine Kinase Inhibitors
- Dasatinib (Sprycel)
- Imatinib (Gleevec)
- Hormonal Therapy
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
Chapter 1 INTRODUCTION
1.1. Report description
1.2. Key benefits
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
Chapter 2 EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
Chapter 3 MARKET OVERVIEW
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Top Player Positioning/ Market Share Analysis, 2017
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. Drug Pipeline Analysis
Chapter 4 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapy Drugs
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Cytarabine
4.2.2.1.1. Market size and forecast
4.2.2.2. Gleevac
4.2.2.2.1. Market size and forecast
4.2.2.3. Sprycel
4.2.2.3.1. Market size and forecast
4.2.2.4. Fludara
4.2.2.4.1. Market size and forecast
4.2.2.5. Others
4.2.2.5.1. Market size and forecast
4.2.3. Market size and forecast, by region
4.3. Anthracycline Drugs
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by type
4.3.2.1. Daunomycin
4.3.2.1.1. Market size and forecast
4.3.2.2. Idarubicin
4.3.2.2.1. Market size and forecast
4.3.2.3. Mitoxantrone
4.3.2.3.1. Market size and forecast
4.3.3. Market size and forecast, by region
4.4. Hormonal Therapy
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.5. Others
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
Chapter 5 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral Drugs
5.2.1. Market size and forecast
5.3. Intravenous Drugs
5.3.1. Market size and forecast
5.4. Others
5.4.1. Market size and forecast
Chapter 6 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY GEOGRAPHY
6.1. Overview
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America acute myeloid leukemia therapeutics market, by country
6.2.2.1. U.S. acute myeloid leukemia therapeutics market
6.2.2.2. Canada acute myeloid leukemia therapeutics market
6.2.2.3. Mexico acute myeloid leukemia therapeutics market
6.2.3. North America acute myeloid leukemia therapeutics market, by type
6.2.4. North America acute myeloid leukemia therapeutics market, by route of administration
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Europe acute myeloid leukemia therapeutics market, by country
6.3.2.1. Germany acute myeloid leukemia therapeutics market
6.3.2.2. France acute myeloid leukemia therapeutics market
6.3.2.3. UK acute myeloid leukemia therapeutics market
6.3.2.4. Italy acute myeloid leukemia therapeutics market
6.3.2.5. Spain acute myeloid leukemia therapeutics market
6.3.2.6. Rest of Europe acute myeloid leukemia therapeutics market
6.3.3. Europe acute myeloid leukemia therapeutics market, by type
6.3.4. Europe acute myeloid leukemia therapeutics market, by route of administration
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Asia-Pacific acute myeloid leukemia therapeutics market, by country
6.4.2.1. Japan acute myeloid leukemia therapeutics market
6.4.2.2. China acute myeloid leukemia therapeutics market
6.4.2.3. India acute myeloid leukemia therapeutics market
6.4.2.4. Australia acute myeloid leukemia therapeutics market
6.4.2.5. South Korea acute myeloid leukemia therapeutics market
6.4.2.6. Rest of Asia-Pacific acute myeloid leukemia therapeutics market
6.4.3. Asia-Pacific acute myeloid leukemia therapeutics market, by type
6.4.4. Asia-Pacific acute myeloid leukemia therapeutics market, by route of administration
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. LAMEA acute myeloid leukemia therapeutics market, by country
6.5.2.1. Brazil acute myeloid leukemia therapeutics market
6.5.2.2. Saudi Arabia acute myeloid leukemia therapeutics market
6.5.2.3. South Africa acute myeloid leukemia therapeutics market
6.5.2.4. Rest of LAMEA acute myeloid leukemia therapeutics market
6.5.3. LAMEA acute myeloid leukemia therapeutics market, by type
6.5.4. LAMEA acute myeloid leukemia therapeutics market, by route of administration
Chapter 7 COMPANY PROFILES
7.1. Ambit Biosciences Corporation
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. Celgene Corporation
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. Teva Pharmaceutical Industries Ltd.
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. Clavis Pharma ASA
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. Eisai Co., Ltd.
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. Sanofi
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. Sunesis Pharmaceuticals, Inc.
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. Novartis AG
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. Bristol-Myers Squibb
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. F. Hoffmann-La Roche AG
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious research methodology
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.
Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast
Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
REQUEST TOC/SAMPLE
Purchase Full Report of
Acute Myeloid Leukemia Therapeutics Market- Global Opportunity Analysis and Industry Forecast, 2019-2026
- Online Only
-
$3,456$3,041 - Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
-
$3,840$3,379 - Restricted to one authorized user
- One print only
- Available in Excel
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
-
$5,370$4,726 - Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
-
$6,450$5,676 - Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF -
$8,995$7,916 - Unlimited within company/enterprise
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Library Access
- $0.00
- Published Content E-Access
- Company Profiles E-Access
- Newly Added Content Access
- 10 PDF Downloads
- 5 Excel Data Pack Downloads
- 250 Company Profiles PDF Downloads
-
Start reading
Buy Now
,This title and over 12000 thousand more,available with Avenue Library, Subcription @ $649 T&C*
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.